Serina Therapeutics Files 8-K on Officer/Director Changes & Shareholder Votes
Ticker: SER · Form: 8-K · Filed: Dec 18, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-director-changes, shareholder-vote
TL;DR
Serina Therapeutics filed an 8-K detailing leadership changes and shareholder votes.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on December 18, 2024, reporting on events that occurred on December 13, 2024. The filing indicates changes related to the departure of directors or officers, the election of directors, the appointment of officers, and compensatory arrangements. It also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This 8-K filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors or officers, and matters submitted to shareholders, can indicate internal shifts or strategic decisions that may affect the company's future performance.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- December 13, 2024 (date) — Earliest event reported
- December 18, 2024 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements.
Were any matters submitted to a vote of security holders?
Yes, the filing confirms the submission of matters to a vote of security holders.
What is the company's principal executive office address?
The principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What is the company's telephone number?
The registrant's telephone number, including area code, is (256) 327-9630.
What was the former name of Serina Therapeutics, Inc.?
The former company name was AgeX Therapeutics, Inc., with a date of name change on June 6, 2017.
Filing Stats: 838 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2024-12-18 16:16:38
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
Filing Documents
- ser-20241213.htm (8-K) — 40KB
- ex101serina2024equityincen.htm (EX-10.1) — 170KB
- 0001708599-24-000029.txt ( ) — 448KB
- ser-20241213.xsd (EX-101.SCH) — 2KB
- ser-20241213_lab.xml (EX-101.LAB) — 53KB
- ser-20241213_pre.xml (EX-101.PRE) — 31KB
- ser-20241213_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The Annual Meeting was held on December 13, 2024. A quorum was present at the meeting. The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting are set forth below. Proposal 1 Election of Three Directors Voting results for the election of directors were as follows: Nominees For Withheld Broker Non-Votes Balkrishan "Simba" Gill 5,998,349 88,715 1,167,580 Remy Gross 5,963,359 123,705 1,167,580 Steven Mintz 5,953,931 133,333 1,167,580 Accordingly, all three of the Company's nominees were elected to serve as directors of the Company until the 2027 Annual Meeting of Stockholders or until their respective successors are appointed, elected and qualified. Proposal 2 Ratification of the Appointment of Auditors Ratification of the appointment of Frazier & Deeter, LLC as the Company's independent registered public accounting firm for the 2024 fiscal year was approved by the following vote: For Against Abstain Broker Non-Votes 7,162,782 90,321 1,541 — Proposal 3 Approval of the Amendment to our 2024 Equity Incentive Plan The Amendment to the Plan was approved by the following vote: For Against Abstain Broker Non-Votes 5,141,448 757,877 187,739 1,167,580
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Serina Therapeutics , Inc. 2024 Equity Incentive Plan, as amended. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: December 18, 2024 By: /s/ Steve Ledger Chief Executive Officer